48 results
8-K
EX-99.1
UNCY
Unicycive Therapeutics Inc
13 May 24
Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update
4:28pm
, safety, and pharmacokinetics of clinically effective doses of OLC in patients with chronic kidney disease (CKD) on dialysis and it remains on track … as a single dose and was chosen as the go-forward dose based on promising safety, tolerability, and pharmacokinetic data. In the multiple ascending
8-K
EX-99.1
UNCY
Unicycive Therapeutics Inc
14 Mar 24
Unicycive Announces $50 Million Private Placement
4:28pm
clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product
8-K
EX-99.1
UNCY
Unicycive Therapeutics Inc
14 Nov 23
Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update
4:42pm
studies were conducted in over 100 healthy volunteers. The first study was a dose-ranging Phase I study to determine safety and tolerability … clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product
8-K
EX-99.1
z2pfdp9m
23 Oct 23
Other Events
11:12am
8-K
EX-99.1
comag
6 Sep 23
Unicycive Therapeutics Strengthens Board of Directors with Appointment of Sara Kenkare-Mitra, PhD
9:16am
8-K
EX-99.1
g5hs923hb8f 8gp0ai
14 Aug 23
Unicycive Announces Second Quarter 2023 Financial Results and Provides Business Update
9:19pm
8-K
EX-99.1
n1okdwod fmg0f6
29 Jun 23
Unicycive Therapeutics Provides Regulatory Update on Lanthanum Dioxycarbonate Program
5:50pm
8-K
EX-99.1
5wptallcgsjbkk
16 May 23
Unicycive Announces First Quarter 2023 Financial Results and Provides Business Update
10:30am
8-K
EX-99.1
soyf8 ley
31 Mar 23
Unicycive Announces Full Year 2022 Financial Results and Provides Business Update
7:47am
8-K
EX-99.1
sl5gdm
29 Dec 22
Unicycive Announces Termination of “At-The-Market” Offering of Shares of Common Stock
12:55pm
8-K
EX-99.2
l903q 1flttto7370u
28 Dec 22
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
9:29am
8-K
EX-99.1
d8l62l g3bf7j5
28 Dec 22
Unicycive Achieves Primary Endpoint in Pivotal Bioequivalence Study of Renazorb
9:29am
8-K
EX-99.1
anq1ts3in5v zur08guj
14 Nov 22
Unicycive Announces Third Quarter Financial Results and Provides Business Update
9:49am